Good Science but Poor Management (Favoritism and Nepotism is Rampant) - werkgeversreview Senior Scientist bij Merck

2,0
4 nov 2018
Aanbevelen
Goedkeuring directeur
Zakelijk vooruitzicht

Pluspunten

Good science, lot of projects to work on and promising portfolio.

Minpunten

Many re-orgs this year. Good people at management level are leaving and people with little or no management skills are given their positions. Favoritism and Nepotism is very rampant - can be seen in who they hire, who is given promotion and who gets the "most visible" projects. Lack of innovation and some projects seem redundant with unnecessary more stress on resources.

Ontdek andere reviews over Merck

5,0
30 jun 2026
Aanbevelen
Goedkeuring directeur
Zakelijk vooruitzicht

Pluspunten

Excellent company to work with.

Minpunten

No cons encountered so far

4,0
30 jun 2026
Aanbevelen
Goedkeuring directeur
Zakelijk vooruitzicht

Pluspunten

Great benefits like medical/dentist/vision, pension, stock option, 401k match. Co workers are excellent, pretty good on site symposiums, lot of diversity clubs/activities. Innovation is extremely welcomed. Diversity in research portfolio. AI/ML is heavily invested to make databases more efficient.

Minpunten

Micro managing, especially within the biologics department, potentially others. Promotions are limited, and pay bump is poor. Company invests too much in buying companies rather than keeping talent - lay offs let go of great talented people. Merck is afraid of investing into exploratory biology and doesn’t take risk - they even admit they would rather see other companies clinical data or R&D data rather than taking a risk. Although it’s slow going in building new software, current databases are slow and needs much improvement. Extremely poor work/life balance.

Bekijk reviews op: Nuttig|Beoordeling|Datum|Alle